Kerry and Luisa re-group after a week apart with updates on “the aesthetics of weight loss” (after time on the road with our Galderma analyst), AbbVie’s opportunity to restore aesthetics harmony (amylin/HarmonyCA), GSK’s acceleration in business development (a new battle of the pills emerging versus Merck’s Winrevair) and more on the TL1A’s in colitis/Crohn’s after breakfast with Teva (Merck & Co, Roche, Sanofi/Teva).